Refractory Knee Osteoarthritis: Adipose‐Derived Stromal Cells Versus Bone Marrow Aspiration Concentrate

Malanga, Gerard A.; Dona, Samuel T.; Borg‐Stein, Joanne; Auriemma, Michael; Singh, Jaspal

doi:10.1016/j.pmrj.2018.03.021

Cited by 6 publications

(4 citation statements)

References 39 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four articles were identified through the reference lists, which gave a total of 29 articles assessed for eligibility. However, five studies were excluded being congress abstracts, one study was excluded because it was a case report [25], and one study was excluded because it provided the same data of another included study [26]. Thus, a total of 22 studies were included in the qualitative data synthesis: 4 preclinical studies [27][28][29][30] and 18 clinical studies [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48].…”

Section: Resultsmentioning

confidence: 99%

Bone marrow concentrate injections for the treatment of osteoarthritis: evidence from preclinical findings to the clinical application

Cavallo

Boffa

Andriolo

et al. 2020

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

Purpose To investigate the available literature on the use of bone marrow aspirate concentrate (BMAC) and summarize the current evidence supporting its potential for the injective treatment of joints affected by osteoarthritis (OA). Methods A systematic literature search was conducted on three electronic databases (PubMed, Embase, and Cochrane Library) in April 2020, using the following string: "((bone marrow concentrate) OR (BMC) OR (bone marrow aspirate concentrate) OR (BMAC)) AND (osteoarthritis)", and inclusion criteria: clinical and preclinical (animal) studies of any level of evidence, written in English language, and evaluating the intra-articular or subchondral use of BMAC for the injective treatment of OA joints. Results The publication trend remarkably increased over time. A total of 22 studies were included in the qualitative data synthesis: four preclinical studies and 18 clinical studies, for a total number of 4626 patients. Safety was documented by all studies, with a low number of adverse events. An overall improvement in pain and function was documented in most of the studies, but the clinical studies present significant heterogeneity, few patients, short-term follow-up, and overall poor methodology. Conclusion There is a growing interest in the field of BMAC injections for the treatment of OA, with promising results in preclinical and clinical studies in terms of safety and effectiveness. Nevertheless, the current knowledge is still preliminary. Preclinical research is still needed to optimize BMAC use, as well as high-level large controlled trials to better understand the real potential of BMAC injections for the treatment of patients affected by OA.

show abstract

Section: Resultsmentioning

confidence: 99%

Bone marrow concentrate injections for the treatment of osteoarthritis: evidence from preclinical findings to the clinical application

Cavallo

Boffa

Andriolo

et al. 2020

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

show abstract

“…Adipose-derived MSCs tend to proliferate more rapidly, are less susceptible to senescence [40,54], and are not affected by the patient's age, sex, and physiological status [55]. A yield of approximately 5% MSCs can be expected in 2 × 10 6 nucleated cells isolated from 1 g of adipose tissue, which is significantly higher than that isolated from other tissues [56]. Adipose tissue is retrieved mostly by lipoaspiration from the abdominal subcutaneous fat.…”

Section: Adipose Tissue Derived Mscsmentioning

confidence: 99%

Method Categorization of Stem Cell Therapy for Degenerative Osteoarthritis of the Knee: A Review

Lee

Shim

Kang

et al. 2021

IJMS

View full text Add to dashboard Cite

Current clinical applications of mesenchymal stem cell therapy for osteoarthritis lack consistency because there are no established criteria for clinical processes. We aimed to systematically organize stem cell treatment methods by reviewing the literature. The treatment methods used in 27 clinical trials were examined and reviewed. The clinical processes were separated into seven categories: cell donor, cell source, cell preparation, delivery methods, lesion preparation, concomitant procedures, and evaluation. Stem cell donors were sub-classified as autologous and allogeneic, and stem cell sources included bone marrow, adipose tissue, peripheral blood, synovium, placenta, and umbilical cord. Mesenchymal stem cells can be prepared by the expansion or isolation process and attached directly to cartilage defects using matrices or injected into joints under arthroscopic observation. The lesion preparation category can be divided into three subcategories: chondroplasty, microfracture, and subchondral drilling. The concomitant procedure category describes adjuvant surgery, such as high tibial osteotomy. Classification codes were assigned for each subcategory to provide a useful and convenient method for organizing documents associated with stem cell treatment. This classification system will help researchers choose more unified treatment methods, which will facilitate the efficient comparison and verification of future clinical outcomes of stem cell therapy for osteoarthritis.

show abstract

“…Orthobiologic injectates for knee OA with less evidence supporting their use include products such as bone marrow aspirate concentrate, microfragmented adipose tissue, amniotic membrane, and umbilical cord. [49][50][51][52] The optimal management of knee OA is an important issue to physiatrists as it is a common cause of loss of function leading to worsening quality of life; however, the optimal treatment algorithm remains unknown. 3,4 Although studies show short-and long-term benefits of manual PT to treat knee OA, 29,30,53 Deyle et al were the first to compare CSI to manual PT for the treatment of knee OA and their article will be reviewed here.…”

mentioning

confidence: 99%

“…Other injectates, including hyaluronic acid 45,46 and platelet rich plasma, 47,48 are supported by evidence and should also be considered in patients with knee OA. Orthobiologic injectates for knee OA with less evidence supporting their use include products such as bone marrow aspirate concentrate, microfragmented adipose tissue, amniotic membrane, and umbilical cord 49–52 …”

mentioning

confidence: 99%

Second-Order Peer Reviews of Clinically Relevant Articles for the Physiatrist

Smith

Schroeder²

2021

Am J Phys Med Rehabil

View full text Add to dashboard Cite

Refractory Knee Osteoarthritis: Adipose‐Derived Stromal Cells Versus Bone Marrow Aspiration Concentrate

Cited by 6 publications

References 39 publications

Bone marrow concentrate injections for the treatment of osteoarthritis: evidence from preclinical findings to the clinical application

Bone marrow concentrate injections for the treatment of osteoarthritis: evidence from preclinical findings to the clinical application

Method Categorization of Stem Cell Therapy for Degenerative Osteoarthritis of the Knee: A Review

Second-Order Peer Reviews of Clinically Relevant Articles for the Physiatrist

Contact Info

Product

Resources

About